CTOs on the Move


 
Apotex is the largest Canadian owned pharmaceutical company, and the largest producer of generic medicines in the country. Founded in 1974, Apotex has steadily grown to employ over 10,000 people around the world, focused on research, development, manufacturing and distribution.
  • Number of Employees: 5K-10K
  • Annual Revenue: $50-100 Million
  • www.apotex.com
  • 150 Signet Drive
    Toronto, ON CAN M9L 1T9
  • Phone: 800.268.4623

Executives

Name Title Contact Details

Similar Companies

Salience Learning

We are Salience Learning. We help solve life science’s most complex business challenges by delivering transformative learning experiences.

RTI Surgical®

RTI Surgical (RTI) is a global, industry leading surgical implant supplier that provides design, new product development, processing and manufacturing services in support of patients and leading medical technology companies. With expertise spanning tis...

Landos Biopharma

Landos pursues safer, more effective first-in-class oral therapeutics for autoimmune disorders at an accelerated rate.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.

Gavis Pharmaceuticals

Gavis Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.